How to Improve the Appearance of Skin

A low pH skin care composition with vitamin B3 and HCA, stabilized by hydrotropes, addresses solubility and stability issues, improving skin appearance and texture synergistically.

JP2024542253AActive Publication Date: 2024-11-13PROCTER & GAMBLE CO

Patent Information

Application Number
JP2024530455
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-29
Filing Date
2022-11-29
Publication Date
2024-11-13
Estimated Expiration
2042-11-29

AI Technical Summary

Technical Problem

Hydroxycinnamic acid (HCA) is insoluble in water and prone to oxidation or degradation at neutral pH, leading to undesirable product changes and reduced effectiveness in skin care compositions, with existing solubility and stability solutions causing sensory issues.

Method used

A low pH skin care composition containing vitamin B3 compounds and HCA, formulated with hydrotropes to enhance solubility and stability, using a pH below 5.0 to prevent crystallization and oxidation.

Benefits of technology

The combination improves skin appearance by enhancing solubility and stability, reducing day-to-day fluctuations, and providing a synergistic effect on skin texture and tone, while maintaining a pleasant sensory experience.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542253000001_ABST
    Figure 2024542253000001_ABST
Patent Text Reader

Abstract

A method for improving the appearance of skin using a low pH skin care composition containing a synergistic combination of hydroxycinnamic acid (HCA) and a vitamin B3 compound is disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for improving the appearance of skin using a low pH skin care composition containing a synergistic combination of stable hydroxycinnamic acid (HCA) and vitamin B3 compounds. [Background technology]

[0002] Skin is the first line of defense against environmental insults that can damage otherwise sensitive underlying tissues and organs. Moreover, skin plays an important role in human physical appearance. Not surprisingly, most people desire healthy and youthful skin. Unfortunately, for some people, the obvious signs of aging, such as thinning skin, wrinkles, and age spots, are undesirable reminders of lost youth. The desire for healthy and youthful looking skin has led to the development of numerous skin care products that are marketed to treat various skin conditions associated with aging and unhealthy skin. These skin care products typically contain one or more active ingredients to treat targeted skin conditions.

[0003] Hydroxycinnamic acids (HCAs) are well-known skin care actives developed for their strong antioxidant properties, as described, for example, in WO 2018 / 081790. However, the use of hydroxycinnamic acids in skin care compositions can be problematic. For example, HCA is relatively insoluble in water, which can lead to the undesirable formation of HCA crystals in the product. Furthermore, when HCA is used at neutral pH (e.g., pH 5.0-8.0), which is becoming more common in certain skin care compositions, HCA can oxidize or decompose, causing undesirable color changes, odor, and / or reduced efficacy of the product. In some cases, formulating the composition at a lower pH can help stabilize HCA, but also reduces the solubility of HCA. There is much interest in overcoming the formulation and stability issues of HCA because of its potential use as a multifunctional skin active ingredient.

[0004] To increase the solubility of HCA, some formulators use additional solvents such as glycols, as described, for example, in U.S. Pat. No. 9,072,919. However, this approach may have undesirable tradeoffs on the sensory profile of the composition. In particular, high levels of glycols may impart an undesirable oily feel to skin care compositions, as glycols are generally not drying and are not quickly absorbed by the skin. Other attempts to address the solubility of hydroxycinnamic acids include formulating the material in the oil phase of the composition (i.e., in the case of emulsions) or encapsulating the material. However, these approaches may also be problematic. For example, adding hydroxycinnamic acids to the oil phase may undesirably affect the sensory profile of the composition due to the introduction of oil and additional emulsifiers into the composition, and encapsulation may reduce the amount of hydroxycinnamic acids in the composition due to encapsulation loading limits. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] International Publication No. 2018 / 081790 [Patent Document 2] U.S. Patent No. 9,072,919 Summary of the Invention [Problem to be solved by the invention]

[0006] Thus, there remains a need to provide methods that provide improved benefits, particularly improved skin appearance, by using aqueous compositions containing hydroxycinnamic acids. [Means for solving the problem]

[0007] Disclosed herein is a method for improving the appearance of skin, comprising identifying a target area of ​​the skin where treatment is desired, and applying a low pH aqueous skin care composition to the target area of ​​the skin for a treatment period. The composition contains a vitamin B3 compound, a hydroxycinnamic acid (HCA), and water, and has a pH of less than 5.0. [Brief description of the drawings]

[0008] [Figure 1A] The HPLC reference spectra of HCA and 4-VP are shown, respectively. [Figure 1B] The HPLC reference spectra of HCA and 4-VP are shown, respectively. [Diagram 2] Solubility of HCA in water over a range of pH. HCA solubility was predicted using Chemicalize (CAS#501-98-4, 7400-08-0), November 2021, https: / / chemicalize.com / , developed by ChemAxon). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] Hydroxycinnamic acid, such as coumaric acid, is known to be a good antioxidant and is commonly used in skin care compositions as such.Surprisingly, it has been recently discovered that a low pH skin care composition containing HCA and niacinamide can synergistically improve the appearance of skin, especially the skin that looks pale and skin texture and / or skin stability.Improved skin stability means reducing the daily fluctuation of skin condition.

[0010] Additionally, in preferred embodiments, it is desirable to improve HCA solubility and / or stability in such compositions in order to deliver further improved synergistic skin appearance benefits.

[0011] Reference herein to "embodiments" or the like means that a particular material, feature, structure, and / or characteristic described in connection with that embodiment is included in at least one embodiment, and optionally in multiple embodiments, but does not mean that all embodiments incorporate the described material, feature, structure, and / or characteristic. Moreover, materials, features, structures, and / or characteristics may be combined in any suitable manner across different embodiments, and materials, features, structures, and / or characteristics may be excluded or substituted from those described. Thus, the embodiments and aspects described herein can include or be combined with elements or components of other embodiments and / or aspects, even if not expressly illustrated in combination, unless otherwise stated or incompatibility is expressly stated.

[0012] In all embodiments, unless otherwise specified, all percentages are by weight of the cosmetic composition. Unless otherwise specified, all ratios are by weight. All ranges are inclusive and combinable. Significant digits do not represent limitations on the amounts listed, nor do they represent limitations on the precision of the measurements. All quantities are understood to be modified by the word "about" unless otherwise specified. Unless otherwise specified, all measurements are understood to be made at ambient conditions of approximately 25°C, where "ambient conditions" refers to conditions of about 1 atmosphere and about 50% relative humidity. All numerical ranges are inclusive of narrower ranges. The upper and lower range limits delimited are interchangeable to create further ranges not expressly delimited.

[0013] The compositions of the present invention can comprise, consist essentially of, or consist of the essential and optional components described herein. As used herein, "consisting essentially of" means that the composition or component may contain additional components, but only if the additional components do not materially alter the basic and novel characteristics of the claimed composition or method. As used in this specification and the appended claims, the singular forms "a," "an," and "the" are intended to include the plural forms unless the context clearly dictates otherwise.

[0014] definition "About" modifies a particular value by referring to a range equal to plus or minus twenty percent (±20%) or less of the stated value (e.g., less than 15%, 10%, or even 5%).

[0015] "Applying" or "application" as used in connection with a composition means applying or spreading a composition of the present invention onto a human skin surface, such as the epidermis.

[0016] "Cosmetic agent" means any substance and any components thereof intended to be rubbed, poured, sprinkled, sprayed, introduced, or otherwise applied to the mammalian body or any part thereof to produce a cosmetic effect. Cosmetic agents can include substances Generally Recognized as Safe (GRAS) by the U.S. Food and Drug Administration, food additives, and materials used in non-cosmetic consumer products, such as over-the-counter drugs.

[0017] "Effective amount" refers to the amount of the compound or composition sufficient to induce a significant positive effect on keratinous tissue over the course of the treatment period. The positive effect can be a health, appearance, and / or feel effect, including the effects disclosed herein, either individually or in combination. In a specific example, the effective amount of vitamin B3 compound is an amount sufficient to improve the health and / or appearance of psoriatic skin during the treatment period. In some examples, the effective amount can be demonstrated using ex vivo and / or in vitro methods.

[0018] "Hydroxycinnamic acids" (HCAs) refer to a class of aromatic acids or phenylpropanoids with a C6-C3 backbone that are hydroxy derivatives of cinnamic acid. Some non-limiting examples of HCAs are caffeic acid, chicoric acid, cinnamic acid, chlorogenic acid, diferulic acid, coumaric acid (p-, o-, and m-), ferulic acid, sinapic acid, sinapic acid, and α-cyano-4-hydroxycinnamic acid.

[0019] "Improving the appearance of" means providing a measurable desired change or effect in the appearance of skin, which can be quantified, for example, by a reduction in redness, inflammation, and / or scaling of spots.

[0020] "Low pH" means a pH below 5.0 (e.g., 1.5-4.9, 2.0-4.5, 2.5-4.0, or 3.5-4.0). Suitable methods for determining the pH of a composition are described in more detail below.

[0021] "Neutral pH" means a pH between 5.0 and 8.0.

[0022] By "safe and effective amount" is meant an effective amount of an ingredient that is low enough to avoid serious side effects (within the scope of sound medical judgment).

[0023] "Skin care" refers to the control and / or improvement of skin condition. Some non-limiting examples include improving the appearance and / or feel of skin by providing a smoother, more uniform appearance and / or feel, increasing the thickness of one or more layers of skin, improving the elasticity or resilience of skin, improving firmness of skin, as well as reducing the oily, shiny, and / or dull appearance of skin, improving skin hydration or moisturization, improving the appearance of fine lines and / or wrinkles, improving skin exfoliation or scaling, plumping skin, improving skin barrier properties, improving skin tone, reducing the appearance of redness or skin blemishes, and / or improving skin brightness, luster, or clarity.

[0024] "Skin care active" means a compound or combination of compounds that, when applied to the skin, produces an acute and / or chronic effect on the skin or a type of cell normally found in the skin. Skin care actives can regulate and / or improve the skin or cells associated therewith (e.g., improve skin elasticity, skin hydration, skin barrier function, and / or cell metabolism).

[0025] "Skin care composition" means a composition that contains skin care actives and that regulates and / or improves the condition of the skin.

[0026] As used herein, "treatment period" refers to the length of time and / or frequency that a material or composition is applied to a targeted skin surface.

[0027] composition The skin care compositions described herein are intended to be topically applied to human skin to improve the appearance, health, and / or function of the skin.The compositions can be used for non-therapeutic (i.e., cosmetic) treatment of various skin conditions.For example, low pH compositions can be particularly suitable for improving the appearance of skin, especially for skin that appears pale and for improving skin texture and / or skin stability.

[0028] The low pH skin care composition herein comprises a safe and effective amount of hydroxycinnamic acid (e.g., p-coumaric acid, also known as 4-HCA or p-HCA), a vitamin B3 compound, and optionally a hydrotrope. The combination of HCA and vitamin B3 compound is specifically tailored to provide a synergistic improvement in skin appearance. In some embodiments, the composition may comprise a silicone emulsifier, a polymeric thickener that can withstand a low pH environment, a low molecular weight silicone fluid, an acid salt pH buffer system (e.g., a lactic acid / sodium lactate buffer system), and / or other ingredients commonly found in topical skin care compositions. Without being bound by theory, it is believed that the combination of ingredients disclosed herein provides a stable and effective skin care composition that has good feel properties and is gentle on the skin.

[0029] Preferably, the low pH composition used in the method herein is formulated to improve HCA solubility in low pH environment. In aqueous low pH skin care compositions, HCA tends to precipitate from the composition and form crystals ("HCA crystals"), which can have an undesirable effect on the appearance, feel, and / or efficacy of the composition. Conventional low pH compositions often contain HCA crystals. However, in a preferred embodiment of the present invention, the low pH composition herein does not contain HCA crystals, since it contains a hydrotrope that is specifically selected to help solubilize HCA and inhibit HCA crystallization. Suitable methods for determining whether a composition does not contain HCA crystals and / or for characterizing HCA crystals in a composition are described in more detail below.

[0030] Preferably, the low pH composition herein is also formulated to improve HCA stability.Because HCA is a relatively good antioxidant, it tends to oxidize and / or decompose over time, which may result in skin care composition showing undesirable color change (e.g., yellowing), undesirable odor, and / or reduced effectiveness.Formulating at lower pH can improve HCA stability by slowing down the rate at which HCA oxidizes, but in some embodiments, it may be desirable to include antioxidant in low pH composition to help further reduce HCA oxidation and / or decomposition.

[0031] The low pH skin care composition herein can be made by mixing the ingredients with dermatologically acceptable carrier using conventional methods known to those skilled in the art.The composition can be provided in various product forms, such as, for example, solution, suspension, lotion, cream, gel, toner, stick, spray, aerosol, ointment, cleansing liquid wash and solid bar, paste, foam, mousse, shaving cream, wipe, strip, patch, powered patch, hydrogel, film-forming product, facial and skin mask (with or without insoluble sheet).The form of the composition can be according to the specific dermatologically acceptable carrier selected.

[0032] In some cases, the low pH skin care composition herein may be in the form of an essence. An essence is a form of topical skin care composition with a relatively thick formulation that is typically less viscous than conventional cream or lotion-type skin care compositions. An essence may be provided in the form of a low-viscosity fluid that is marketed to specifically target a particular skin condition and / or is used as the first step in a skin care regimen. The skin care essence product herein may have a kinetic viscosity of 1 centipoise (cP) to 15,000 cP (e.g., 50 cP to 10,000 cP, or 100 cP to 7,500 cP, 200 cP to 5,000 cP, or 300 cP to 2,500 cP) at 25°C. Methods for determining the viscosity of low pH compositions are described in more detail in the Methods section below.

[0033] Hydroxycinnamic Acid The low pH skin care compositions herein include a safe and effective amount of HCA. HCA may be present in the composition at 0.1% to 10% (e.g., 0.5% to 5% or 1% to 4%). Hydroxycinnamic acids are generally recognized as antioxidant phenolic compounds and may be found in plants primarily as components of cell walls. See HK Kuzaki et al., J. Agric. Food Chem., 50, 2161-68 (2002). In some embodiments, it may be desirable to select coumaric acid, particularly p-coumaric acid (also known as 4-HCA), for use in low pH compositions. p-Coumaric acid has the following structure:

[0034] [ka]

[0035] In other embodiments, it may be desirable to use a mixture of two or more HCAs, such as a mixture of coumaric acid and ferulic acid. In these embodiments, the coumaric acid and ferulic acid may be present in a weight ratio of 2:1 to 1:2 (e.g., 1:1). A particularly suitable example of an HCA material suitable for use herein is LIPOBRITE, available from Vantage Personal Care.

[0036] Vitamin B3 Compounds The composition comprises 0.1% to 10% (e.g., 0.5% to 5% or 1% to 4%) of a vitamin B3 compound. As used herein, a "vitamin B3 compound" refers to a compound having the formula:

[0037] [ka] During the ceremony, R refers to compounds, derivatives thereof, and salts of any of the foregoing, in which R is CONH2 (i.e., niacinamide), COOH (i.e., nicotinic acid), or CH2OH (i.e., nicotinyl alcohol). Exemplary derivatives of vitamin B3 compounds include nicotinic acid esters, including non-vasodilatory esters of nicotinic acid (e.g., tocopheryl nicotinate, myristyl nicotinate), nicotinamide riboside, nicotinyl amino acid, nicotinyl alcohol esters of carboxylic acid, nicotinic acid N-oxide, and niacinamide N-oxide. In some cases, vitamin B3 compounds such as niacinamide may have improved efficacy at relatively low pH, as described, for example, in US Patent Application Publication No. 2020 / 0009123.

[0038] In some cases, it may be desirable for the ring nitrogen of the vitamin B3 compound to be "uncomplexed" (e.g., chemically unbound and / or unhindered) in the composition and / or prior to application to the target skin surface. For example, the compositions herein may be free or substantially free (i.e., less than 3%, 2%, 1%, or even less than 0.5%) of salts or complexes of the vitamin B3 compound. Exemplary methods for minimizing or preventing the formation of undesirable salts and / or complexes include removing substances that form substantially irreversible or other undesirable complexes with the vitamin B3 compound in the composition, adjusting pH, adjusting ionic strength, using surfactants, and implementing a formulation process in which the vitamin B3 compound and the substances that complex with it are in different phases.

[0039] Hydrotropes HCA compounds generally exhibit particularly low solubility in low pH aqueous compositions, such as the low pH compositions described herein. For example, p-coumaric acid has a solubility of about 345 mg / mL in water at pH 7.0 and 20°C, and a solubility of 4 mg / mL in water at pH 3.0 and 20°C. Without being bound by theory, it is believed that the reduced solubility of HCA at lower pH is due to the reduced ability of HCA to undergo acid dissociation to form conjugate base species observed at higher pH levels. At pH 7, about 99.6% of coumaric acid is present in its conjugate base form, while at pH 3, only about 13.4% of the conjugate base form is present. As a result of this relatively low solubility, HCA tends to form crystals in aqueous low pH skin care compositions. HCA crystals can impart an undesirable feel to the composition during use (e.g., a rough or grainy feel) and / or reduce the efficacy of HCA and / or other ingredients in the composition. This can cause an undesirable consumer perception of poor product quality.

[0040] The compositions herein may include 0.1%-10% (e.g., 0.5%-5% or 1%-3%) of a hydrotrope to enhance the aqueous solubility of HCA. In some embodiments, the hydrotrope may be a phenolic acid (e.g., salicylic acid) or a salt thereof (e.g., sodium salicylate). If the hydrotrope contains a conjugate base of a phenolic acid, the hydrotrope must have a pKA below the formulation pH and have sufficient intrinsic water solubility at the formulation pH to completely dissolve. Having an acidic pKa that is below the pH of the composition may be particularly important for low pH compositions, since the solubility of HCA is low at low pH. For example, sodium salicylate, with a pKa of 2.8, would be a suitable hydrotrope for use in a composition with a pH of 3.8, since the bound carboxylic acid exists primarily in the conjugate base form. In contrast, sodium cinnamate, with an acidic pKa of 4.32, respectively, would not be an effective hydrotrope in this example. Additionally, the hydrotrope should be selected to help improve the sensory appeal of the composition by reducing the need for other solubilizers such as glycols. Some non-limiting examples of hydrotropes that may be suitable for use herein are salicylic acid, 2,4 dihydroxybenzoic acid, 2,3 dihydroxybenzoic acid, 3-methoxysalicylic acid, salts thereof, or combinations thereof. Other non-limiting examples of hydrotropes that may be suitable for use herein are disclosed in WO 2018 / 081790.

[0041] Antioxidants The low pH compositions herein may include antioxidants to combat oxidation and / or degradation of HCA. When included, antioxidants may be present at 0.001% to 3% (e.g., 0.01% to 2%, 0.05% to 1%, or 0.1% to 0.5%). Some non-limiting examples of antioxidants that may be suitable for use herein are sodium sulfite, sodium bisulfite, sodium metabisulfite, and butylated hydroxytoluene.

[0042] Low pH acid buffer system When providing a low pH composition for topical application to the skin, it may be important to include a buffer system that helps maintain the pH of the composition for a period of time (e.g., up to 5 minutes or more) after application to the skin. On average, the pH of human skin is typically in the range of about 5.0 to 6.0. To maintain this pH, human skin has evolved a natural buffer system that resists changes in pH. Thus, when a low pH composition is applied to the skin, the skin's natural buffer system attempts to adjust the pH of the composition to match the skin's natural pH. A low pH composition may not be able to provide the desired skin care benefits without the addition of a buffering agent. Thus, the compositions herein may include a low pH acid buffer system.

[0043] The buffering agent may be selected depending on the acid used to lower the pH of the low pH composition herein. For example, lactic acid and gluconic acid may be used to lower the pH of the composition, as they are generally considered to be gentler on the skin (i.e., less risk of irritation) compared to other alpha hydroxy acids. In this example, sodium lactate or sodium gluconate would be selected to provide an acid / salt pH buffer system. The salt buffering agent may be present in the low pH composition at 0.25% to 4% (e.g., 0.5% to 3%, 0.75% to 2%, or 1% to 1.75%). Non-limiting examples of low pH buffering systems suitable for use herein are disclosed in co-pending U.S. Patent Application No. 16 / 891,491. Of course, it should be understood that the present composition may optionally include other pH buffers known for use in skin care compositions.

[0044] Thickener The composition includes a polymeric thickener that can withstand low pH electrolytic environments. That is, the thickener does not lose its ability to thicken or stabilize the composition at low pH in the presence of an acid-salt buffer system. Some conventional neutralized thickeners are known to degrade and / or lose their ability to adequately thicken the composition at lower pH and / or in the presence of acid salt buffers (e.g., sodium lactate). For example, some neutralized thickeners decompose in low pH environments. On the other hand, fatty alcohol thickeners such as cetyl alcohol and stearyl alcohol are generally stable at low pH, but tend to impart undesirable haze or opacity to the composition when in the form of an essence, serum, etc. It has also been found that certain anionic polymeric thickeners can provide suitable resistance to low pH environments, but cannot withstand buffer systems due to the combination of acid and salt. Thus, in some cases, the low pH compositions described herein may be free or substantially free of neutralized thickeners, fatty alcohol thickeners, and anionic thickeners. The thickening agent may be present at from 0.0001% to 25% by weight (eg, from 0.001% to 20%, from 0.01% to 10%, from 0.5% to 7%, or even 1% or 5% by weight) of the composition.

[0045] Other non-limiting examples of thickening or water structuring agents that can be used herein, alone or in combination, include natural or synthetic gums, polysaccharides, carboxylic acid polymers, polyacrylamide polymers, sulfonated polymers, and copolymers thereof. Further examples include modified gums, cellulose, and superabsorbent polymers. The term "superabsorbent polymer" is understood to mean a polymer that is capable of spontaneously absorbing at least 20 times its own weight in an aqueous fluid, particularly water, especially distilled water, in a dry state. Suitable polysaccharides include alkyl hydroxyalkyl cellulose ethers, such as hydroxypropyl methylcellulose stearoxy ether. This material is sold under the trade names SANGELOSE 60L and 90L by Daido Chemical Corp. Another suitable polysaccharide includes hydrophobically modified starches, such as modified potato starch. This material is sold under the trade name STRUCTURE SOLANACE by Nouryon. Alternative polymers include crosslinked polymers in which the monomers are at least partially composed of acryloyldimethyltaurate monomers, such as, for example, sodium polyacryloyldimethyltaurate, sold, for example, under the trade name ARISTOFLEX SILK by Clariant.

[0046] It has been found that certain anionic polymer thickeners can provide compositions with suitable resistance to low pH environments, as well as desirable feel and opacity.Thus, a particularly suitable example of an anionic thickener is polyacrylate crosspolymer-6, available as SEPIMAX ZEN from Seppic, France.

[0047] A low molecular weight silicone fluid. In some cases, anionic polymer thickeners can impart an undesirable sticky feel when the low pH composition is applied to the target area of ​​the skin. It has been found that the addition of a low molecular weight silicone fluid can reduce or prevent this sticky feel. The molecular weight of the silicone fluid depends on the length of its silicone polymer chain, which is also directly proportional to the viscosity of the silicone fluid. Thus, low molecular weight silicone fluids suitable for use in the present low pH compositions have a kinematic viscosity of 100 cSt or less (e.g., 1 cSt to 90 cSt, 5 cSt to 50 cSt, or even 10 cSt to 30 cSt) at 25°C. Kinematic viscosity is a common way of classifying silicone fluids and can be obtained from material suppliers. A particularly suitable example of a low molecular weight silicone fluid is 5 cSt dimethicone fluid. As used herein, "dimethicone" refers to a silicone fluid having the formula

[0048] [ka] The compound having the formula:

[0049] Dermatologically acceptable carrier The low pH compositions herein may include a dermatologically acceptable carrier (sometimes referred to as a "carrier"). The phrase "dermatologically acceptable carrier" means that the carrier is suitable for topical application to keratinous tissue, has good aesthetic properties, is compatible with the actives in the composition, and does not raise any undue safety or toxicity concerns. In one embodiment, the carrier is present in a concentration of about 50% to about 99%, about 60% to about 98%, about 70% to about 98%, or alternatively about 80% to about 95% by weight of the composition.

[0050] The carrier may be in a wide variety of forms. In some cases, the solubility or dispersibility of the components (e.g., extracts, sunscreen actives, additional ingredients) may determine the form and characteristics of the carrier. Non-limiting examples include simple solutions (e.g., aqueous or anhydrous), dispersions, emulsions, and solid forms (e.g., gels, sticks, flowable solids, or amorphous materials). In some cases, the dermatologically acceptable carrier is in the form of an emulsion. An emulsion may have a continuous aqueous phase (e.g., oil-in-water or water-in-oil-in-water emulsions) or a continuous oil phase (e.g., water-in-oil or oil-in-water-in-oil emulsions). The oil phase of the present invention may include non-silicone oils such as silicone oils, hydrocarbon oils, esters, ethers, and mixtures thereof. The aqueous phase typically includes water and water-soluble components (e.g., water-soluble moisturizers, conditioning agents, antibacterial agents, humectants, and / or other skin care actives). In some cases, however, the aqueous phase may contain components other than water, including, but not limited to, water-soluble moisturizers, conditioning agents, antimicrobial agents, humectants, and / or other water-soluble skin care actives. In some cases, the non-aqueous components of the composition include humectants, such as glycerin and / or other polyol(s).

[0051] In some cases, the compositions herein are in the form of oil-in-water ("O / W") emulsions that provide a light, non-greasy sensory feel. Suitable O / W emulsions herein may comprise more than 50% by weight of the composition of a continuous water phase, with the remainder being a dispersed oil phase. The water phase may comprise 1% to 99% water, based on the weight of the water phase, along with any water-soluble and / or water-miscible ingredients. In these cases, the dispersed oil phase is typically present at less than 30% by weight of the composition (e.g., 1% to 20%, 2% to 15%, 3% to 12%, 4% to 10%, or even 5% to 8%) to help avoid some of the undesirable sensory effects of oil-based compositions. The oil phase may comprise one or more volatile and / or non-volatile oils (e.g., vegetable oils, silicone oils, and / or hydrocarbon oils). Some non-limiting examples of oils that may be suitable for use in the present compositions are disclosed in U.S. Pat. No. 9,446,265 and U.S. Patent Application Publication No. 2015 / 0196464.

[0052] The carrier may contain one or more dermatologically acceptable hydrophilic diluents. As used herein, "diluents" include materials in which the vitamin B3 compound can be dispersed, dissolved, or otherwise incorporated. Hydrophilic diluents include organic hydrophilic diluents such as water, lower monohydric alcohols (e.g., C1-C4), and low molecular weight glycols and polyols, including propylene glycol, polyethylene glycol (e.g., molecular weight 200-600 g / mol), polypropylene glycol (e.g., molecular weight 425-2025 g / mol), glycerol, butylene glycol, 1,2,4-butanetriol, sorbitol esters, 1,2,6-hexanetriol, ethanol, isopropanol, sorbitol esters, butanediol, ether propanol, ethoxylated ethers, propoxylated ethers, and combinations thereof.

[0053] emulsifier When the low pH compositions herein are in the form of an emulsion (e.g., an oil-in-water emulsion), it may be desirable to include an emulsifier to stabilize the emulsion (i.e., prevent the emulsion from phase separating). The emulsifier may be present in the composition at 0.01% to 10% (e.g., 0.05% to 5%, or 0.1% to 2%). The emulsifier may be nonionic, anionic, or cationic. In some cases, the emulsifier may be a silicone emulsifier. Some non-limiting examples of emulsifiers that may be suitable for use herein are disclosed in U.S. Pat. Nos. 3,755,560, 4,421,769, and McCutcheon's Detergents and Emulsifiers, North American Edition, pages 317-324 (1986).

[0054] Some other non-limiting examples of emulsifiers that may be suitable for use herein include ethers of polyglycols and ethers of fatty alcohols, esters of polyglycols and esters of fatty acids, ethers of polyglycols and ethers of glycosylated fatty alcohols, esters of polyglycols and esters of glycosylated fatty acids, ethers of C12-30 alcohols and ethers of glycerol or polyglycerol, esters of C12-30 fatty acids and esters of glycerol or polyglycerol, ethers of oxyalkylene modified C12-30 alcohols and ethers of glycerol or polyglycerol, ethers of C1-230 fatty alcohols including sucrose or glucose, ethers of sucrose or ethers of glucose, esters of sucrose and esters of C1230 fatty acids, esters of pentaerythritol and esters of C12-30 fatty acids, esters of sorbitol and / or esters of sorbitan and C12 Examples of emulsifiers include esters of C12-30 fatty acids, ethers of sorbitol and / or ethers of sorbitan and alkoxylated sorbitan, ethers of polyglycols and ethers of cholesterol, esters of C12-30 fatty acids and alkoxylated ethers of sorbitol and / or sorbitan, and combinations thereof. A particularly useful class of emulsifiers are polyethylene glycol ethers of lauryl alcohol, such as laureth-1 to laureth-50 (e.g., laureth-4). Still other examples of emulsifiers include ethers of glycerol, polyglycerol, sucrose, glucose, or sorbitol; esters of glycerol, polyglycerol, sucrose, glucose, or sorbitol; and mixtures thereof. Another particularly useful class of emulsifiers are alkyl esters of sorbitol and sorbitol anhydrides, such as polysorbate 20, polysorbate 21, and polysorbate 40.

[0055] In some embodiments, it may be desirable to include linear or branched silicone emulsifier in low pH composition.Particularly useful silicone emulsifiers include polyether-modified silicones such as KF-6011, KF-6012, KF-6013, KF-6015, KF-6015, KF-6017, KF-6043, KF-6028 and KF-6038, and polyglycerol-modified linear or branched siloxane emulsifiers such as KF-6100, KF-6104 and KF-6105 (all from Shin-Etsu).The emulsifier particularly suitable for use herein is PEG-11 methyl ether dimethicone, sold by Shin-Etsu as KF-6011. Surprisingly, it has been found that the PEG-11 methyl ether dimethicone emulsifier improves the overall feel of the low pH composition by further reducing the sticky feel of the anionic polymer thickener. The emulsifier may be present in an amount of 0.1% to 10% (e.g., 1% to 5%, or 2% to 4%).

[0056] Co-solvents In some embodiments, the compositions herein may include a short chain dihydric alcohol (e.g., glycol) co-solvent to aid in solubilizing the HCA. However, when selecting a glycol as a co-solvent, it may be important to limit the amount of glycol to less than 25% (e.g., less than 20%, less than 17%, less than 15%, or even less than 10%) to reduce the risk of imparting undesirable sensory characteristics (e.g., sticky or greasy) to the composition. Some non-limiting examples of glycols that may be suitable for use herein are propylene glycol, dipropylene glycol, butylene glycol, pentylene glycol, hexylene glycol, ethoxydiglycol, and C2-C6 polyethene glycols (e.g., PEG-3, PEG-4, PEG-4 methyl ether), and combinations thereof.

[0057] Other Optional Ingredients The composition may optionally include one or more additional ingredients commonly used in cosmetic compositions (e.g., colorants, skin care actives, anti-inflammatory agents, sunscreens, emulsifiers, buffers, rheology modifiers, combinations thereof, etc.), provided that the additional ingredients do not undesirably alter the skin health or appearance benefits provided by the composition. If incorporated into the composition, the additional ingredients should be suitable for use in contact with human skin tissue without undue toxicity, incompatibility, instability, allergic response, etc. Some non-limiting examples of additional actives include vitamins, minerals, peptides and peptide derivatives, sugar amines, sunscreens, oil control agents, microparticles, flavonoid compounds, hair growth regulators, antioxidants and / or antioxidant precursors, preservatives, protease inhibitors, tyrosinase inhibitors, anti-inflammatory agents, moisturizers, exfoliants, skin lightening agents, sunless tanning agents, lubricants, anti-acne actives, anti-cellulite actives, chelating agents, anti-wrinkle actives, anti-atrophy actives, phytosterols and / or plant hormones, N-acyl amino acid compounds, antibacterial agents, and antifungal agents. Other non-limiting examples of additional ingredients and / or skin care actives that may be suitable for use herein are described in U.S. Patent Application Publication Nos. 2002 / 0022040, 2003 / 0049212, 2004 / 0175347, 2006 / 0275237, 2007 / 0196344, 2008 / 0181956, 2008 / 0206373, 2010 / 00092408, 2008 / 0206373, 2010 / 0239510, 2010 / 0189669, 2010 / 0189702, 2010 / 0189704, 2010 / 0189706, 2010 / 0189708, 2010 / 0189709 ... Nos. 2010 / 0272667, 2011 / 0262025, 2011 / 0097286, 2012 / 0197016, 2012 / 0128683, 2012 / 0148515, 2012 / 0156146, and 2013 / 0022557, as well as U.S. Patent Nos. 5,939,082, 5,872,112, 6,492,326, 6,696,049, 6,524,598, 5,972,359, and 6,174,533.

[0058] When optional ingredients are included in the compositions herein, it may be desirable to select ingredients that do not complex or otherwise interact undesirably with other ingredients in the composition at low pH, particularly pH-sensitive ingredients such as niacinamide, salicylates, and peptides. In some cases, it may be desirable to select skin care actives that function via different biological pathways so that the actives do not interfere with each other, which may reduce the effectiveness of both agents. When present, optional ingredients may be included in an amount of 0.0001% to 50%, 0.001% to 20%, or even 0.01% to 10% (e.g., 50%, 40%, 30%, 20%, 10%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.1%) by weight of the composition.

[0059] How to use The low pH cosmetic compositions herein are formulated for topical application to the skin. A method of using the low pH compositions of the present invention includes identifying a target area of ​​skin on a person in need of treatment or where treatment is desired (e.g., paleness, hyperpigmented spots, enlarged pores, or uneven skin color or texture) and applying an effective amount of the low pH composition to the target area of ​​skin for a treatment period. The effective amount of the composition may vary based on the skin effect desired by the user and / or the size of the treatment area. In some cases, the effective amount may range from 0.1 g to 5 g (e.g., 0.2 g to 4 g, 0.3 g to 2 g, or even 0.5 g to 1 g). The target area of ​​skin may be on the skin surface of the face, such as the forehead, perioral, chin, periorbital, nose, and / or cheeks, or on another part of the body (e.g., hands, arms, legs, back, chest). In some cases, the target area of ​​skin may be selected that is an area of ​​skin that does not currently show signs of skin aging, but will commonly exhibit such characteristics with age. In these cases, low pH compositions can be used to prevent the development of such undesirable skin characteristics.

[0060] The composition can be applied topically to the target area of ​​the skin in need of treatment and, optionally, to the surrounding skin at least once a day, twice a day, or more frequently every day during the treatment period. If applied twice a day, the first and second applications are separated by at least 1-12 hours. The composition is typically applied in the morning and / or at night before going to bed. When used according to the methods herein, the composition can improve the appearance and / or function of the skin, for example, by improving the texture of the skin. The improvement of the skin texture may be achieved, for example, by reducing the size of pores, reducing roughness, reducing the presence and / or size of wrinkles, combinations thereof, and the like.

[0061] The treatment period is ideally long enough for the low pH composition to improve the appearance and / or function of the target area of ​​the skin. The treatment period typically lasts for at least one week (e.g., about 2, 4, 8, or even 12 weeks). In some cases, the treatment period may extend for multiple months (i.e., 3-12 months). In some cases, the composition is applied at least once a day or even twice a day on the majority of days of the week (e.g., at least 4, 5, or 6 days a week) during the treatment period of at least 2, 4, 8, or 12 weeks.

[0062] The step of applying the composition herein can be performed by topical application. With respect to the application of the composition, the terms "topical", "topical" or "topically" mean that the composition is delivered to a target area (e.g., psoriasis plaque) while minimizing delivery to skin surfaces where treatment is not desired. The composition can be applied to a skin area and gently massaged. The form of the composition or dermatologically acceptable carrier should be selected to facilitate topical application. Although certain embodiments herein contemplate applying the composition locally to an area, it will be understood that the composition herein can also be applied systemically or broadly to one or more skin surfaces. In certain embodiments, the composition herein can be used as part of a multi-step cosmetic regimen, in which the composition can be applied before and / or after one or more other compositions.

[0063] method HPLC This method provides a method for determining the weight percent of HCA and 4-vinylphenol (4-VP), respectively, in a raw material or final product using high performance liquid chromatography ("HPLC"). The method can also be used to identify HCA and / or 4VP by matching their wavelength spectra and retention times to their respective known standards. The following equipment and materials are used in this method:

[0064] device: A gradient HPLC system including a gradient HPLC pump, a liquid autosampler, a UV detector (and a diode array detector (DAD) for spectral analysis), and a suitable computing integrator or computer data system (e.g., a Waters 2695 HPLC system or equivalent from Waters Corporation). · 5um, 250mm x 4.6mm ID HPLC column (e.g., C18 column from Alltech Alltima).

[0065] method: Two mobile phases are used to create a gradient with a consistent flow rate of 1.0 mL / min. Mobile phase A consists of 0.5% acetic acid in purified water. Mobile phase B consists of 0.5% acetic acid in acetonitrile. The gradient is shown in Table 1 below.

[0066] [Table 1]

[0067] Calculation: 1. Calculate the weight percent of HCA in the test sample

[0068]

number

[0069]

number

[0070] Crystallization of HCA This method provides a method for determining the solubility of HCA in a composition by observing HCA crystals in situ.This method involves cycling the temperature of a test sample between freezing and thawing to simulate the environmental conditions experienced by skin care compositions at an accelerated rate.This type of accelerated deterioration is commonly used in cosmetic stability testing.HCA crystals can be detected using conventional means such as visual observation and microscopy.

[0071] A bulk sample of at least 10 g (e.g., 20 g to 60 g) of the composition to be tested is placed in a suitable container (e.g., a clear plastic or glass jar) that allows for visual observation of the test sample. The test sample is subjected to a one-month freeze / thaw temperature cycle to simulate the environmental conditions that a skin care product may experience during shipping and storage. This is sometimes referred to as accelerated aging. The temperature cycle includes a one-week freeze cycle at -7°C, followed by a one-week thaw cycle at 25°C, and then the freeze / thaw cycle is repeated for a total temperature cycle period of one month.

[0072] Upon completion of the accelerated aging process (i.e., one month of temperature cycling), the transparent test samples are visually inspected in situ in a transparent container to determine whether crystallization / precipitation of HCA has occurred. For opaque and translucent samples, the entire test sample is removed from the container, transferred to a suitable transparent substrate (e.g., plastic film or glass plate) and cast into a thin film of 1 mm or less in thickness. The sample is covered with a second transparent substrate to inhibit loss of volatile components during inspection. To aid in visual inspection, the sample is backlit using a light source (e.g., LED lamp, etc.). HCA crystals generally appear as precipitates in the composition that are visible to the naked eye when observed by a person with 20 / 20 vision from a distance of 45 cm. Any precipitates identified during visual observation may be further evaluated using a microscope capable of providing fluorescence birefringence observation with cross-polarized light to identify anisotropic crystals. Any anisotropic crystals having a longest dimension greater than 0.1 mm are identified as HCA crystals, and the total number of HCA crystals is recorded. Test samples containing 1 or less HCA crystal are considered "HCA crystal free" and are recorded as a "pass." Test samples containing more than 1 HCA crystal are recorded as a "fail."

[0073] Although not required, Fourier transform infrared spectroscopy (FTIR) may be used to confirm that HCA crystal or co-crystal contains the appropriate hydroxycinnamic acid structure.FTIR spectroscopy is well known in the art.See U.S. Patent No. 10,912,857, U.S. Patent Application Publication No. 2020 / 0000697, and Fourier Transform Infrared Spectroscopy in Colloid and Interface Science, DRS Cheuing, Ed., American Chemical Society, 225, 1991.

[0074] color This method can be used to determine the color change of a product, material, or substrate. A spectrophotometer (e.g., Spectrophotometer CM-3600A, Konica Minolta, Japan, or equivalent) is used to measure spectral data under CIE (International Commission on Illumination) specified lighting and viewing conditions, and calculate the associated tristimulus values ​​XYZ based on the CIE observer and CIE illuminant standard. The ASTM standard for obtaining spectral data to evaluate the color of an object is ASTM E1164-12(2017)e1, and the values ​​and procedures for calculating the CIE tristimulus values ​​from the spectral data are outlined in ASTM E308. * a * b * The CIELAB color scale, also known as the CIELAB scale, is calculated from tristimulus values ​​defined in ASTM E308. * indicates the perceived lightness of the sample. * and b * is related to the inherent color of human vision, and a * is positive in the red direction and negative in the green direction, and b * is positive in the yellow direction and negative in the blue direction.

[0075] The spectrophotometer is operated with a 2° observer and D65 illuminant to measure tristimulus XYZ values ​​and associated CIELAB colors as defined in 1931 CIE. The aliquots are evaluated using a 10 mm path length in a plastic cell (e.g., CM-A131, Konica Minolta, Japan, or equivalent), reflectance measurements, a 25.4 mm aperture at the specimen surface, and no specular component with a standard white background. Acceptable white backgrounds include the white portion of an opaque card or equivalent (e.g., opaque card type 2A, Leneta Company, Inc, Mahwah, NJ). A dust- and debris-free zero calibration box or black trap (e.g., Konica Minolta zero calibration box CM-A155 or equivalent) is utilized to calibrate the instrument with a zero standard. CIELAB values ​​are reported by the associated instrument software (e.g., SpectroMagic NX) as defined in ASTM E308. The yellowness change of the product is measured using a 10 mm path length in a plastic cell (e.g., CM-A131, Konica Minolta, Japan, or equivalent), a 25.4 mm aperture aperture at the specimen surface, and a standard white background. Acceptable white backgrounds include the white portion of an opaque card or equivalent (e.g., opaque card type 2A, Leneta Company, Inc, Mahwah, NJ). A dust- and debris-free zero calibration box or black trap is utilized to calibrate the instrument with a zero standard. CIELAB values ​​are reported by the associated instrument software (e.g., SpectroMagic NX) as defined in ASTM E308.* Use the CIELAB color scale to focus on the change in value. * and positive Δb * indicates an increase in yellowness.

[0076] Rheology This method provides a method for measuring the kinematic viscosity of a composition or material using a BROOKFIELD brand viscometer (such as Model DV2T or equivalent) and a suitable spindle (such as RV4 or equivalent) according to the manufacturer's instructions. It is understood that one of ordinary skill in the art can select an appropriate spindle according to the manufacturer's recommendations. After calibrating the viscometer, immerse the spindle in a sufficient amount of test sample (e.g., a sufficient amount to immerse the spindle up to the dip mark on the spindle shaft). Set the spindle rotation speed to 5 rpm and start the viscometer. Wait until the displayed viscosity reading stabilizes (approximately 10 to 30 seconds). Once the reading stabilizes, take five readings at 10-second intervals. Calculate the viscosity as the average of the five readings.

[0077] Skin stability measurement method Skin appearance stability was measured using eMR Pro, a self-diagnostic facial imaging system developed by P&G Company (Kobe, Japan) (IP Application Docket No. AA1280) and further described in Miyamoto, Kukizo, et al., "Daily fluctuation of facial pore area, roughness and redness among young Japanese women; Beneficial effects of Galactomyces ferment filtrate containing antioxidative skin care formula," Journal of clinical medicine 10.11 (2021):2502. The method utilizes a commercially available smartphone camera / LED illumination source (iPhone 7 / 8 / SE) with a plastic attachment on the cheek area of ​​the face. The attachment is attached to control the intensity of the LED light illuminating the skin surface. In addition, a color chip is present for image standardization of each image. A small repositionable mirror and an automatic eye / face live view recognition algorithm are incorporated into the eMR application program. The captured images (1080 x 1920 pixels) are encrypted and then analyzed after the regions of interest are masked, aligned, and color standardization is completed. The device allows for an increased number of measurements to be taken by panelists themselves at home. A plastic face attachment ensures a constant distance between the camera head and the skin surface. As described in the following sections, pores, blemishes, and wrinkles are captured. * , a * , b * Image analysis methods are performed to measure skin characteristics such as color, etc., and uneven appearance.

[0078] The method used to define uneven appearance utilizes entropy statistics and is described in U.S. Patent No. 11348366(B2). As used herein, the term entropy refers to the Shannon entropy (E) of a discrete random distribution (p(x)) and is defined by the following formula:

[0079]

number

[0080] In a non-limiting example where the digital image is an RGB image, the entropy (entropy value) for each R (red), G (green), and B (blue) channel can be calculated separately. The entropy value of the image can be calculated at each pixel location (i,j) by calculating the entropy value of the pixel values ​​in a two-dimensional region centered at (i,j). The two-dimensional region may be a portion of the color channel image. A programming software package such as Python can be used to calculate the entropy value. The color channels can be analyzed separately to isolate distinct tonal and texture inhomogeneities. Once an image is acquired with red, green, and blue color channels, it can be extracted using the L2D filter for further descriptive analysis. * a * b * The red color channel can be converted to color coordinates. * a * b * When in a color system, a entropy is the entropy value of the filtered red color channel. When the yellow color channel is L * a * b * When in a color system, the b entropy is the entropy value of the filtered yellow color channel. When the blue color channel corresponds to the texture channel, the c entropy is the entropy value of the blue color channel.

[0081] The measure of variability for characterizing skin stability from the acquired time series data used to characterize skin stability is the mean absolute difference for a given measured endpoint.

[0082]

number

[0083]

number

[0084] Each measurement is taken at different and consistent time points throughout the day.In the described embodiment, the measurement set is the morning before washing face, the morning after washing face, and the night after washing face.Then, the daily variation is calculated by using the mean absolute difference formula for a certain time point (e.g., the night after washing face).Programming software such as Python can be used to calculate the mean absolute difference. EXAMPLES

[0085] Example 1: Formulations. Table 2 below provides examples of low pH skin care compositions corresponding to various aspects of the present invention. The compositions can be prepared using conventional methods of manufacturing skin care compositions. Such methods typically include mixing the ingredients in one or more steps to a relatively homogeneous state, with or without heating, cooling, application of vacuum, and the like. All exemplified amounts exclude minor materials such as diluents, preservatives, color solutions, feel-adjusting powders, and elastomers that may be present in commercial products, unless otherwise specified. HCA may be added as a solid form and solubilized in situ, dissolved as a premix, or supplied as a predispersed raw material. Certain examples use a 15% solution of 4-HCA predispersed in PEG-4 (Lipobrite® from Vantage). For examples containing Lipobrite®, the component levels of 4-HCA and PEG-4 are listed individually for clarity, with superscripts indicating the Lipobrite® raw material. Total Lipobrite® material added is the sum of the 4-HCA and PEG-4 components listed. All other materials are listed "as is" from the supplier and have not been broken down into individual components.

[0086] The emulsion is prepared by first mixing the water phase materials separately from the oil phase and / or silicone phase materials, then combining the two phases appropriately to obtain the desired continuous phase. In some embodiments, the exemplary composition can be made by blending the water phase components with a suitable mixer (e.g., IKA RW20 or equivalent) until all materials are dissolved and homogeneous. If present, the optional polymeric thickener can be hydrated by slowly adding the thickener directly to the water phase with stirring and continuing to mix until homogeneous. The 4-HCA, hydrotrope, and optional glycol can be added together in a separate premix container and mixed until completely dissolved and homogeneous. In some embodiments, the hydrotrope can be pre-neutralized to form a suitable salt (e.g., sodium salicylate) to facilitate mixing / solubilization. The HCA premix can then be added to the main mixing container and further mixed until homogeneous. The formulation may be milled using a suitable mixer (e.g., an IKA Ultra Turrax T-25 or equivalent) to reduce the emulsion particle size until the target viscosity is reached and a uniform composition is obtained. The temperature may be adjusted as necessary to control the speed of the process and / or to obtain a homogenous final product.

[0087] [Table 2]

[0088] [Table 3] 1 SEPIMAX ZEN available from Seppic 2 ARISTOFLEX SILK available from Clariant 3 Shin-Etsu KF-6011 4 Vantage LIPOBRITE (15% 4-HCA, 85% PEG-4) 5 Dow Corning DC 1503 6 PROMATRIXYL from Croda 7 Ferulic acid from Sigma Aldrich * Adjust pH as needed

[0089] Example 2: Δb * and synergistic reduction in skin texture. This example demonstrates the ability of the low pH composition herein to provide synergistic improvement in the appearance of pale-looking skin in clinical trials. Three independent clinical trials were conducted to investigate the beneficial skin effects provided by the compositions of the present invention. Each clinical trial was a 9-week in vivo study using a randomized, vehicle-controlled, round-robin, split-face design, with a 1-week washout period and an 8-week test period. All results reported are from the 8-week test period. The minimum base size per study was 40 subjects. The treatment regimen began with a 1-week washout period. Subjects were instructed to wash their face every morning and evening with a standard cleanser (Olay Deep cleansing facial Cleanser, The Procter & Gamble Company), gently towel dry, and apply a standard moisturizer (containing 3% glycerin) to both sides of the face. At baseline, each subject received two coded test formulations to be applied twice daily to either the left or right side of the face. Each morning and evening, subjects washed their face with a standard cleanser, gently towel dried, and applied 0.5 g of the appropriate test formulation to both sides of the face, using gentle finger pressure and circular movements. Positive and negative (vehicle) controls were used in each test. The positive control was a neutral pH composition containing 5% niacinamide and 1% undecylenoyl phenylalanine (SEPIWHITE from Seppic), a known skin brightener. Test section A contained 0.9% coumaric acid (6% LIPOBRITE from Vantage), test section B was a low pH (3.8) composition containing 2% niacinamide, and section C was a low pH composition of the present invention containing 2% niacinamide and 1% coumaric acid (6.67% LIPOBRITE). The test results are summarized in Tables 3 and 4.

[0090] Images of the facial treatment sites were taken at baseline and at 8 weeks of treatment to assess changes in skin color (b * Decrease in value and L *The changes to the facial texture and the increase in the facial brightness (increase in the facial brightness) were analyzed as described below ("imaging method"). Prior to image collection, participants washed their faces with a mild cleanser and then allowed to equilibrate for approximately 20 minutes before imaging. Images of the right and left sides of the participants' faces were then collected using a digital camera (e.g., a Canon EOS-6D DSLR or similar) fitted with an appropriate lens for facial imaging (e.g., a 60 mm NIKKOR lens or similar) and attached to a standardized lighting and imaging system with head positioning. A suitable imaging design is the Canfield VISIA and / or OLE imaging system, or a similar imaging system capable of standardized and reproducible imaging. The Canfield VISIA and OLE imaging systems (Canfield Scientific, Inc., Parsippany, New Jersey, USA) are designed to capture reproducible facial images under controlled lighting and head positioning configurations in clinical research studies. Both the VISIA and OLE imaging systems incorporate a Canon EOS-6D DSLR that uses a 21 megapixel CMOS sensor with a maximum resolution of 5472 x 3648. The VISIA and OLE imaging systems store both Exif JPEG and Canon raw image files for each captured image.

[0091] Images of the subjects were collected under various lighting modalities to provide better visualization of the skin features under investigation. Automatic flash selection and changeable filter controls selected the correct combination of lighting, lighting angle and filters optimized to provide better imaging of facial topographical features (wrinkles, texture, etc.) or facial color features (blemishes, color tone, etc.). A live feed image of the subject superimposed on the baseline image was used to improve reproducibility between time points. The subject was positioned such that all of the major landmarks on the face in the live image were precisely aligned with the same landmarks in the baseline image. Each image included a color chart with color chips of known values ​​to aid in color management. Images captured on the VISIA and OLE imaging systems using Canfield Capture software were saved directly to a data drive on the imaging system computer.

[0092] In this example, the regions of interest (ROIs) for color and texture measurements covered the upper and lower cheeks of the subjects, but did not extend to the lower eye area and the central crow's feet. The upper limit of the mask was along the upper cheekbones of the subjects. The specific differences in the ROIs were attributed to the differences in the facial morphology of the subjects. Yellowness (b * ) and lightness (L * ) from the cross-polarized images that highlight the base skin color via image analysis, and the average b * Value and L * The change in yellowness (Δb * ) and change in brightness (ΔL * ) was calculated as the change from baseline at the desired time point (in this case, 8 weeks). For between-study comparisons, results were adjusted to vehicle control to account for any study differences and are reported as change from control (treatment effect minus control effect).

[0093] The results in Tables 3 and 4 are the Δb * Change and ΔL *The changes in mean and associated p-values ​​comparing test sections and vehicle control, respectively. Statistical analysis was performed using a mixed model with subject (fitted as a random effect), baseline, treatment and cheek left / right (fitted as fixed effects) as covariates at each time point. The significance level was set at 0.10 (2-tailed) for test comparisons such that a p-value of less than 0.10 was statistically significant. The expected values ​​were Δb * The synergy coefficient is calculated by dividing the observed value (Test Section C) by the expected value. A synergy coefficient greater than 1 indicates a synergistic effect.

[0094] As can be seen in Table 3, test section A showed a small but significant b * In test category B, b * Surprisingly, the composition of the present invention in Test Section C exhibited a much greater reduction in b than expected, as evidenced by a synergy coefficient of 3.03. * The value of b in this specification has been reduced. * A preferred decrease in value is -0.200 or more (eg, -0.300, -0.400, -0.500, or even -1.0 or more).

[0095] [Table 4]

[0096] Skin whitening (L * Regarding the L value, Test Section A did not show any skin whitening effect at 8 weeks, while Test Section B showed a very strong skin whitening effect. Surprisingly, the composition of the present invention in Test Section C showed much more L whitening effect than expected, as evidenced by the synergy coefficient of 2.35. * The L * A suitable increase in value is 0.2 or more (eg, 0.2, 0.4, 0.6, or even 1.0 or more).

[0097] [Table 5]

[0098] The appearance of skin texture was also assessed in the study. The method for determining texture area fraction uses standardized, reproducible image capture and objective image analysis methods as outlined above. The degree of skin texture within the ROI was objectively quantified using image analysis algorithms based on the Optimus software platform. This analysis identified skin surface texture patterns that correlate with human texture perception and quantified the total texture area detected in pixels. Because ROIs vary in shape and size from subject to subject, the total texture area was normalized to the total ROI size and the Texture Area Fraction (TAF), i.e., the percentage of the ROI area that is facial texture, in pixels, was calculated. A summary of the results is shown in Table 5.

[0099] As can be seen in Table 5, the compositions of the present invention synergistically improved the percent texture area compared to the values ​​of the comparative test sections. Comparative test section A did not improve the appearance of skin texture, while test section B provided a significant improvement in the appearance of skin texture. Surprisingly, test section C provided a synergistic improvement in the appearance of skin texture. A preferred reduction in texture values ​​herein is -0.200 or more (e.g., -0.300, -0.400, -0.500, or even -1.0 or more).

[0100] [Table 6]

[0101] Example 3: Effect of pH and Niacinamide on HCA Stability This example demonstrates the effect of pH and niacinamide on HCA stability.When HCA decomposes (e.g., via decarboxylation), it produces 4-vinylphenol (4-VP) as a by-product, which is generally undesirable in skin care compositions.4-VP can cause unpleasant odors in the composition, and can also react to cause discoloration (e.g., yellowing) of the composition.Therefore, it may be desirable to limit the amount of 4-VP in skin care compositions to less than 1500 ppm (e.g., less than 1100, 800 ppm, 700 ppm, 600 ppm, 500 ppm, 400 ppm, or even less than 300 ppm).

[0102] The compositions in Table 6 were tested to determine the effect of pH and niacinamide on the degradation of HCA and the formation of 4-VP. The pH of the test compositions was adjusted as necessary using 6N HCL or 4% NaOH solution. The test compositions were incubated at 50° C. for 3 weeks and then the color change (Δb * ) was tested according to the color method described above.

[0103] [Table 7]

[0104] As can be seen from Table 6, both pH and niacinamide have an effect on HCA degradation, Δb *, and appears to affect 4-VP formation. These data suggest that increasing pH and / or adding niacinamide increases the decomposition of 4-HCA, increases the formation of 4-VP, and causes yellowing in aqueous skin care compositions. Unexpectedly, the data show that adding niacinamide actually accelerates the formation of 4-VP at higher pH. This is unexpected, since niacinamide was never previously known to contribute to, let alone accelerate, HCA decomposition. Thus, lowering the pH of a skin care composition containing HCA and niacinamide appears to unexpectedly reduce the rate of formation of 4-VP.

[0105] The data in Table 6 also show that both pH and niacinamide have an effect on the yellowness (Δb * Surprisingly, at a pH of 3.8 to 6.0 (e.g., about 4.5), the test compositions containing niacinamide showed a significant change in Δb * The yellowing associated with HCA decomposition (i.e., Δb * This result is surprising since the pH (positive change in pH value) was expected to vary with pH in a predictable linear manner, as seen for compositions 6D-6F.

[0106] Example 4: Effect of radical scavengers on yellowing rate. This example demonstrates a reduction in the yellowing rate (i.e., a lower Δb * The results demonstrate the ability of antioxidants to assist in reducing HCA degradation as evidenced by the Δb values. The test compositions shown in Table 7 below were tested at pH 3.8 and pH 6.0, both with and without sodium metabisulfite, an oxygen interference reducer. The test compositions were aged under two different accelerated aging conditions: 50° C. for 3 weeks (3W50C) and 40° C. for 3 months (3M40C). Without being bound by theory, it is believed that the accelerated aging conditions simulate environmental conditions that skin care products may be exposed to during shipping and storage. After accelerated aging, the test compositions were tested according to the color method described above to measure Δb *The test compositions aged at 40° C. for 3 months were further tested according to the HPLC method to determine the levels of HCA degradation and 4-VP formation.

[0107] The test results are summarized in Table 7 below. As can be seen from Table 7, the addition of sodium metabisulfate (SMBS) significantly reduced the yellowing rate of 7B and 7D compared to compositions 7A and 7C, respectively. Surprisingly, the data shows that the effect of the oxygen interference reducer was more enhanced than expected at low pH relative to neutral pH (i.e., 20% for 3W50C and 240% for 3M40C, as can be seen from Table 7). Δb * The reduction in yellowing appears to be due to some other unique mechanism of action rather than a further reduction in HCA degradation or 4-VP formation. Thus, it is now possible to provide a combination of ingredients that can synergistically reduce the rate of yellowing in low pH compositions containing HCA.

[0108] [Table 8]

[0109] The synergistic results from the studies in this example are shown in Table 8. The synergy coefficient is calculated by dividing the observed value by the predicted value. A synergy coefficient greater than 1 indicates a synergistic effect.

[0110] [Table 9]

[0111] Example 5: Low pH solubility This example demonstrates the ability of the low pH compositions herein to solubilize HCA at low pH. As shown in FIG. 2, HCA solubility begins to decrease dramatically at about pH 6.0. However, the low pH compositions can keep HCA solubilized at low pH (e.g., pH 3.8) as a result of high concentrations of glycol co-solvents (ethoxydiglycol and PEG-4). To accelerate the instability of HCA, the test compositions shown in Table 9 were subjected to two 1 week / 1 week freeze / thaw cycles at -7°C / 25°C for a total of 1 month of temperature cycling. As seen in Table 9, certain test compositions passed the HCA crystallization test until the glycol co-solvent concentration was reduced to such a concentration that HCA was not solubilized.

[0112] [Table 10]

[0113] Example 6: Effect of Glycol Cosolvents and Phenolate Hydrotropes on HCA Solubility This example demonstrates how glycols can improve the solubility of HCA. It is desirable to formulate HCA-containing compositions at lower pH to reduce 4-VP formation and yellowing, but the solubility of HCA at low pH may not be sufficient to add it at the level required for effective skin care actives. As in Example 5, the test compositions shown in Table 10 were subjected to two 1 week / 1 week freeze / thaw cycles at -7°C / 25°C for a total of 1 month of temperature cycling. In this example, phenolic acids are neutralized with aqueous base (e.g., sodium hydroxide) to form the ionized salt form of the species in situ during batch production. The test results are summarized in Table 10 below.

[0114] As can be seen from Table 10, the combination of the present invention containing the suitable combination of hydrotrope and glycol co-solvent does not contain HCA crystals ("pass"), while the comparative example shows crystal formation ("fail"). The combination of ethoxydiglycol and sodium salicylate was able to solubilize 0.5% HCA in a low pH aqueous composition, even when the level of glycol co-solvent alone was not sufficient. Furthermore, as can be seen from the data, the addition of sodium salicylate reduces the amount of glycol to solubilize HCA, and more importantly, it remains below levels (e.g., <25% combined glycol co-solvents) that may cause undesirable sensory issues. Other well-known hydrotropes, such as caffeine and niacinamide, are unable to solubilize HCA, even at higher levels (5%). Testing additional phenolic acids and phenolic alcohols should reveal that phenolic acids with pKas below the formulation pH (3.8 in this case) are more effective at solubilizing HCA than other conventional hydrotropes or chemicals of similar structural characteristics.

[0115] [Table 11]

[0116] [Table 12] * Sodium hydroxide used as a pH adjuster as needed to achieve the desired pH level and neutralize phenolic acids

[0117] Example 7: Solubility effects of mixed HCAs. This example demonstrates that the solubility of a 50:50 mixture of coumaric acid and ferulic acid is unexpectedly improved, even in the absence of a hydrotrope. The test compositions shown in Table 11 were subjected to two freeze / thaw cycles of 1 week / 1 week at -7°C / 25°C, for a total of 1 month of temperature cycling. As can be seen from Table 11, test composition 11B did not show significant HCA crystallization, even in the absence of additional hydrotropes or polar emollients, and the combination of ferulic acid and coumaric acid in composition 11B appears to provide a synergistic enhancement of HCA solubility.

[0118] [Table 13]

[0119] Example 8: Comparative Example This example demonstrates the inability of conventional compositions to solubilize HCA at low pH. Example 2 of US Patent Application Publication No. 2014 / 0107046 was prepared as described in the application, along with several variations of its formulation (Examples A-K). The test compositions are shown in Table 12 below. The test compositions were subjected to two freeze / thaw cycles of 1 week / 1 week at -7°C / 25°C, followed by a rest period of 90 days at 25°C. The compositions were then tested for the presence of HCA crystals, as described above. As can be seen from Table 12, all of the comparative compositions exhibited crystallization / precipitation. Even when p-coumaric acid was used instead of ferulic acid, as in comparative compositions C, I, and J, the comparative compositions still exhibited HCA crystallization. Thus, none of the comparative compositions exhibit the desired HCA solubility provided by the low pH compositions herein.

[0120] [Table 14]

[0121] [Table 15]

[0122] Example: Increasing Skin Appearance Stability In vivo imaging studies were performed using the eMR Pro device detailed in the Methods Overview section and used to test visual skin appearance stability by measuring daily appearance variability. Studies were performed with a base size of 66 study panelists who were healthy Japanese women aged 22-35 years. For recruitment, panelists self-reported at least two of the following skin problems on their cheeks (uneven skin tone, dark spots, visible pores, overall oily skin). Exclusion criteria included illness, pregnancy, skin disease or allergies, currently receiving treatment from a dermatologist, history of cosmetic surgery / procedures, experience of redness, tightness, or flaking of the skin after washing the face, self-reported dry skin, and experience of >5 large acne lesions (>2mm per side of the face) consistently.

[0123] The study was a split face round robin design across three treatments detailed in Table 13. The formulations tested included a placebo section (composition A), low pH niacinamide (composition B), and low pH niacinamide + HCA (composition C). Product treatments were randomized by combination and face side. Consumers used eMR Pro to take photos of the left and right cheeks three times a day (morning: before washing after removing facial oils with tissue paper, morning: after washing for more than 5 minutes, evening: after washing for more than 5 minutes).

[0124] [Table 16]

[0125] The study included a 4-week standardization period, during which consumers were given a consistent baseline regimen that included a commercially available makeup removal oil, cleansing foam, toner, emulsion, and sunscreen for 4 weeks. After the standardization period, consumers added the essence / serum formulation of Table 13 to the regimen. The test product was then used for another 4 weeks to evaluate skin stability by variability measurement.

[0126] Statistical analysis was performed using a mixed model with subject as a random effect and baseline unevenness, treatment, and cheek left / right as fixed effects as covariates at each time point. The significance level was 0.10 (2-sided) for all test comparisons, with p-values ​​less than 0.10 considered statistically significant. Adjusted means and comparison p-values ​​are reported in Tables 14, 15, and 16. Results for comparison differences are identified as either vehicle control, normalization period, or treatment comparisons.

[0127] [Table 17]

[0128] [Table 18]

[0129] [Table 19]

[0130] Examples / Combinations 1. A method for improving the appearance of skin, comprising: a) identifying a target area of ​​the skin where treatment is desired; b) applying a low pH aqueous skin care composition to the target area of ​​the skin for a treatment period, wherein the composition comprises: i) about 0.1% to about 10% of a vitamin B3 compound; ii) about 0.1% to about 10% hydroxycinnamic acid (HCA); and iii) water, wherein the pH of the composition is less than 5.0. 2. The method according to the preceding features, wherein improving the appearance of the skin is improving pale looking skin, improving skin texture, and / or improving skin stability. 3. The method according to any of the preceding features, wherein improving the appearance of the skin is improving pale looking skin. 4. The method comprises, during the treatment period, * Decreased value, L* The method according to any of the preceding features, providing at least one of an increase in skin texture value, or a decrease in skin texture value. 5. According to the imaging method, * The decrease in value is at least -0.20 and L * The method according to any of the preceding features, wherein the increase in value is at least 0.25 and / or the decrease in skin texture value is at least -0.25. 6.b * Decreased value, L * The method of any of the preceding features, wherein the increase in value and / or decrease in skin texture value is synergistic. 7. The method of any of the previous aspects, wherein the composition does not contain HCA crystals. 8. The method of any of the preceding features, wherein the vitamin B3 compound is niacinamide. 9. The method of any of the previous features, wherein the composition further comprises a hydrotrope selected from salicylic acid, 2,4 dihydroxybenzoic acid, 2,3 dihydroxybenzoic acid, 3-methoxysalicylic acid, salts thereof, and combinations thereof. 10. The method of any of the previous features, wherein the composition further comprises less than 25% of a glycol co-solvent. 11. The method of any of the preceding features, wherein the co-solvent is selected from the group consisting of propylene glycol, dipropylene glycol, butylene glycol, pentylene glycol, hexylene glycol, ethoxydiglycol, C2-C6 polyethene glycol, and combinations thereof. 12. The method of any of the previous features, wherein the composition further comprises about 1% to about 20% by weight of an antioxidant. 13. The method of any of the previous features, wherein the antioxidant is selected from the group consisting of sodium sulfite, sodium bisulfite, sodium metabisulfite, and combinations thereof. 14. The method according to any of the preceding features, wherein the pH is from about 2.0 to about 4.5. 15. The method of any of the previous features, wherein the HCA is coumaric acid. 16. The method of any of the previous features, wherein the composition exhibits less than 25% HCA degradation according to the HPLC method. 17. The method of any of the preceding features, wherein the composition contains less than 1000 ppm of 4-vinylphenol. 18. A method for improving the appearance of skin, comprising: a) identifying a target area of ​​the skin where treatment is desired; b) applying a low pH aqueous skin care composition to the target area of ​​the skin for a treatment period, wherein the composition comprises: i) a vitamin B3 compound; ii) a mixture of coumaric acid and ferulic acid, the ratio of coumaric acid to ferulic acid being from about 2:1 to about 1:2; and iii) water, wherein the composition has a pH of about 5.0 or less. 19. The method of claim 18, wherein the weight ratio of coumaric acid to ferulic acid is about 1:1. 20. The method comprises, during the treatment period: * Value, L * 20. The method of claim 18, further comprising providing a synergistic improvement in at least one of the skin texture value and the skin texture value. 21. The method of claim 18, wherein the composition further comprises a hydrotrope selected from salicylic acid, 2,4 dihydroxybenzoic acid, 2,3 dihydroxybenzoic acid, 3-methoxysalicylic acid, salts thereof, and combinations thereof. 22. The method of claim 18, wherein the composition does not contain HCA crystals.

[0131] Dimensions and values ​​disclosed herein should not be understood as being strictly limited to the exact numerical values ​​recited. Instead, unless otherwise specified, each such dimension is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a dimension disclosed as "40 mm" is intended to mean "about 40 mm."

[0132] All documents cited herein, including any cross-referenced or related patents or patent applications, and any patent applications or patents to which this application claims priority or benefit, are incorporated herein by reference in their entirety, unless expressly stated to the contrary. The citation of any document shall not be deemed to be prior art to any invention disclosed or claimed herein, or to teach, suggest, or disclose any such invention, either alone or in combination with any other reference or references. Furthermore, to the extent that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition given to that term in this document shall govern.

[0133] While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.

Claims

1. 1. A method for improving the appearance of skin, comprising: a) identifying a target area of ​​the skin where treatment is desired; b) applying a low pH aqueous skin care composition to said target area of ​​skin for a treatment period, said composition comprising: i) from about 0.1% to about 10% of vitamin B 3 A compound, ii) about 0.1% to about 10% hydroxycinnamic acid (HCA); and iii) water, wherein the pH of the composition is less than 5.

0.

2. 2. The method of claim 1, wherein improving the appearance of the skin comprises improving pale looking skin, improving skin texture, and / or improving skin stability.

3. 3. The method of claim 2, wherein improving the appearance of the skin is improving pale looking skin.

4. The method further comprises, during the treatment period, * Decrease in value, L * The method of claim 1 , further comprising providing at least one of an increase in skin texture value or a decrease in skin texture value.

5. According to the imaging method, b * said decrease in value is at least -0.20, L * The method of claim 4, wherein said increase in value is at least 0.25 and / or said decrease in skin texture value is at least -0.

25.

6. b * The decrease in value, L * The method of claim 4 , wherein the increase in value and / or decrease in skin texture value is synergistic.

7. The method of claim 1 , wherein the composition is free of HCA crystals.

8. Vitamin B 3 2. The method of claim 1, wherein the compound is niacinamide.

9. 10. The method of claim 1, wherein the composition further comprises a hydrotrope selected from salicylic acid, 2,4 dihydroxybenzoic acid, 2,3 dihydroxybenzoic acid, 3-methoxysalicylic acid, salts thereof, and combinations thereof.

10. The method of claim 1 , wherein the composition further comprises less than 25% of a glycol co-solvent.

11. 11. The method of claim 10, wherein the co-solvent is selected from the group consisting of propylene glycol, dipropylene glycol, butylene glycol, pentylene glycol, hexylene glycol, ethoxydiglycol, C2-C6 polyethene glycol, and combinations thereof.

12. The method of claim 1 , wherein the composition further comprises from about 1% to about 20% by weight of an antioxidant.

13. 13. The method of claim 12, wherein the antioxidant is selected from the group consisting of sodium sulfite, sodium bisulfite, sodium metabisulfite, and combinations thereof.

14. 2. The method of claim 1, wherein the pH is from about 2.0 to about 4.

5.

15. 2. The method of claim 1, wherein the HCA is coumaric acid.

16. 10. The method of claim 1, wherein the composition exhibits less than 25% HCA degradation according to an HPLC method.

17. The method of claim 1, wherein the composition comprises less than 1000 ppm of 4-vinylphenol.

18. 1. A method for improving the appearance of skin, comprising: a) identifying a target area of ​​the skin where treatment is desired; b) applying a low pH aqueous skin care composition to said target area of ​​skin for a treatment period, said composition comprising: i) a vitamin B3 compound; and ii) a mixture of coumaric acid and ferulic acid, the ratio of coumaric acid to ferulic acid being from about 2:1 to about 1:2; and iii) water, wherein the composition has a pH of about 5.0 or less.

19. 20. The method of claim 18, wherein the weight ratio of coumaric acid to ferulic acid is about 1:

1.

20. The method further comprises, during the treatment period, * Value, L * 20. The method of claim 18, wherein the method provides a synergistic improvement in at least one of skin texture value and skin texture value.

21. 20. The method of claim 18, wherein the composition further comprises a hydrotrope selected from salicylic acid, 2,4 dihydroxybenzoic acid, 2,3 dihydroxybenzoic acid, 3-methoxysalicylic acid, salts thereof, and combinations thereof.

22. 20. The method of claim 18, wherein the composition is free of HCA crystals.

Citation Information

Patent Citations

  • Improved cosmetic composition containing vitamin b3, vitamin b6 and organic acid

    JP2007509899A

  • Cosmetic composition containing at least one flavonoid and ferulic acid

    JP2015533169A

  • Compositions containing phenolic compounds with synergistic antioxidant effects

    JP2019532982A

  • Composition with less odor

    JP2020093991A

  • Stable composition containing combination of specific components

    JP2021095354A

Cited By

  • Methods for Treating Post-Acne Scars

    JP2024538842A

  • Skin Care Composition

    JP2024541369A

  • Methods for treating post-acne scars

    JP7806240B2

  • Skincare composition

    JP7911068B2